272 related articles for article (PubMed ID: 17367921)
21. Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Choi J; Kang M; Nam SH; Lee GH; Kim HJ; Ryu J; Cheong JG; Jung JW; Kim TY; Lee HY; Lee JW
Lung Cancer; 2015 Oct; 90(1):22-31. PubMed ID: 26190015
[TBL] [Abstract][Full Text] [Related]
22. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
23. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
24. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
25. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
26. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Marshall J
Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
[TBL] [Abstract][Full Text] [Related]
28. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
30. Overview of tyrosine kinase inhibitors in clinical breast cancer.
Agrawal A; Gutteridge E; Gee JM; Nicholson RI; Robertson JF
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S135-44. PubMed ID: 16113090
[TBL] [Abstract][Full Text] [Related]
31. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Grünwald V; Hidalgo M
J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
[TBL] [Abstract][Full Text] [Related]
32. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
Tortora G; Gelardi T; Ciardiello F; Bianco R
Int J Biol Markers; 2007; 22(1 Suppl 4):S47-52. PubMed ID: 17520581
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML; Giaccone G
Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
[TBL] [Abstract][Full Text] [Related]
34. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.
Diasio RB; Fourie J
Drugs; 2006; 66(11):1441-63. PubMed ID: 16906777
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.
Feiner RC; Müller KM
Expert Rev Proteomics; 2016 Sep; 13(9):817-32. PubMed ID: 27424502
[TBL] [Abstract][Full Text] [Related]
36. Mini-review: bmx kinase inhibitors for cancer therapy.
Jarboe JS; Dutta S; Velu SE; Willey CD
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):228-38. PubMed ID: 23198769
[TBL] [Abstract][Full Text] [Related]
37. [Potential combination of target therapy and radiation therapy in GI tract cancers].
Maingon P; Créhange G; Peignaux K; Truc G
Cancer Radiother; 2008 Jan; 12(1):25-30. PubMed ID: 18226575
[TBL] [Abstract][Full Text] [Related]
38. Integration of EGFR inhibitors with radiochemotherapy.
Nyati MK; Morgan MA; Feng FY; Lawrence TS
Nat Rev Cancer; 2006 Nov; 6(11):876-85. PubMed ID: 17036041
[TBL] [Abstract][Full Text] [Related]
39. [Epidermal growth factor receptor and radiotherapy].
Sirák I; Hatlová J; Petera J; Vosmik M; Ryska A; Vosmiková H
Klin Onkol; 2008; 21(6):338-47. PubMed ID: 19382597
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase D as a potential new target for cancer therapy.
LaValle CR; George KM; Sharlow ER; Lazo JS; Wipf P; Wang QJ
Biochim Biophys Acta; 2010 Dec; 1806(2):183-92. PubMed ID: 20580776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
